Prostate cancer is the most common cancer in UK men, and London's Royal Marsden and Guy's and St Thomas' manage thousands of mCRPC patients. Abiranamo offers London patients this treatment at dramatically reduced cost for private or supplementary access.
While NICE-approved Zytiga is available on the NHS for eligible patients, London's private prostate cancer patients face costs exceeding £3,500 monthly. Generic Abiranamo from WHO-GMP certified manufacturers provides identical clinical outcomes at a fraction of this cost.
|
FAQ: Can I take Abiranamo alongside NHS-prescribed
treatments? This should always be
coordinated with your NHS oncology team. If you're accessing Abiranamo
privately while also under NHS oncology care, inform your treating team so
blood tests, side effect monitoring, and any other medications can be properly
coordinated and there's no duplication of therapy. |
